• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Probiotics not effective in preventing necrotizing enterocolitis: The PiPS trial

byMelissa McCoyandXiaozhou Liu
December 1, 2015
in Emergency, Gastroenterology, Infectious Disease, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this multicenter, randomized controlled phase 3 study [PiPS trial], the primary outcomes of rates of necrotizing enterocolitis, blood culture positive sepsis more than 72 hours after birth, and death before discharge did not differ significantly between preterm infants receiving probiotic B breve (BBG-001) and those receiving placebo.

2. There were no probiotic-associated adverse events

Evidence Rating Level: 1 (Excellent)

Study Rundown: Previous trials have shown probiotics to be beneficial in reducing necrotizing enterocolitis and late-onset sepsis. The recommendation for the routine use of probiotic B breve in all preterm infants is supported by a recent Cochrane review including 24 studies and 5,500 infants. In this randomized controlled phase 3 study, the investigators aimed to assess whether probiotic Bifidobacterium breve BBG-001 was effective in reducing the primary outcomes of necrotizing enterocolitis, late onset sepsis, and death in preterm infants. Infants born between 23 to 30 weeks’ gestation were recruited and assigned to receive either probiotic (experimental group) or placebo (control group). The primary outcomes did not differ significantly in rates of occurrence. A strength of this study was its statistical power and its representation of the population at large. A weakness of this study is that the high colonization rate of the placebo group may have masked the benefits of the probiotic intervention.

The study was funded by UK National Institute for Health Research Health Technology Assessment Programme.

Click to read the study in The Lancet

Relevant Reading: Probiotics for prevention of necrotizing enterocolitis preterm infants

RELATED REPORTS

Probiotic Bifidobacterium infantis EVC001 associated with decrease in necrotizing enterocolitis

Meta-analysis highlights health benefits of probiotics and prebiotics in premature infants

Increased survival without major morbidity noted among very low birthweight infants in California

In-Depth [randomized controlled trial]: This multicenter, randomized controlled phase 3 trial aimed to assess the effectiveness of the probiotic Bifodobacterium breve BBG-001 in preventing the primary outcomes of necrotizing enterocolitis (Bell stage 2 or 3), blood culture positive sepsis more than 72 hours after birth; and death before discharge from hospital. Between 7/1/2010 and 7/31/2013, 1,315 Infants were allocated (1:1) to either experimental group (probiotic B breve BBG-001) or control group (dilute infant formula).

Primary outcomes between probiotic and placebo groups did not differ significantly. 61 (9%) infants in the probiotics group had necrotizing enterocolitis compared with 66 (10%) in the placebo group (adjusted risk ratio 0.93 [95% CI 0.68–1.27]); 73 (11%) infants in the probiotic group had sepsis compared with 77 (12%) in the placebo group (0.97 [0.73–1.29]); 54 (8%) deaths before discharge occurred in the probiotic group compared with 56 (9%) in the placebo group (0.93 [0.67–1.30]). Additionally, no benefit was detected for any secondary outcomes, including other measures of sepsis. Rate of other major neonatal morbidities were similar between the groups. There were two serious adverse events – one episode of toxic epidermal necrolysis and one massive pulmonary hemorrhage; however, these were considered unlikely to be related to the interventions.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: necrotizing enterocolitis
Previous Post

Increased cigarette tax linked to decreased infant mortality

Next Post

2 Minute Medicine Rewind November 30, 2015

RelatedReports

Probiotics improve colic, reduce GI disorders in infants
Gastroenterology

Probiotic Bifidobacterium infantis EVC001 associated with decrease in necrotizing enterocolitis

January 20, 2022
Probiotics improve colic, reduce GI disorders in infants
Pediatrics

Meta-analysis highlights health benefits of probiotics and prebiotics in premature infants

December 15, 2020
Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial
Pediatrics

Increased survival without major morbidity noted among very low birthweight infants in California

June 18, 2020
Low evidence for glycerin use in preterm infants
Gastroenterology

Low evidence for glycerin use in preterm infants

May 18, 2015
Next Post
Adjuvant radiation decreases local recurrence in low-risk breast cancer

2 Minute Medicine Rewind November 30, 2015

Better cardiorespiratory fitness in young adulthood improves long-term outcomes

Better cardiorespiratory fitness in young adulthood improves long-term outcomes

Unmet healthcare need in adolescence linked to poor adult outcomes

Increased clinician computer-use linked to lower patient-reported satisfaction

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.